ArticleEuropean journal of nuclear medicine and molecular imaging2025
The utility of [
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic ablative radiotherapy (SABR) is used in patients with early-stage primary lung cancer who are not fit for surgery or who refuse surgery. Post-treatment, patients are monitored with surveillance CT, with [
methodsThis is a dual-centre retrospective study of 754 consecutive patients who received SABR for lung lesions in our institutions between 2012 and 2023. Seventy-four FDG PET-CT scans from 65 patients, performed at a median of 585 days after SABR were included. SUVmax and subjective score of likelihood of recurrence were recorded. Follow-up imaging, biopsy and resection histology, where available, were used to ascertain the patients' outcome.
resultsOut of 74 included FDG PET-CT scans, there were 11 local recurrences and 63 non-recurrences by reference standard. The SUVmax of the lesion post-SABR was significantly higher in patients who had recurrent tumour (median 4.3, range 2.2-16.1) compared to those who did not (median 3.3, range 1.4-6.4) (p = 0.011). Subjective scores of likelihood of recurrence performed better than SUVmax readings alone with positive and negative predictive values of 0.45 and 0.96, respectively, which are significantly improved to 0.94 and 1.00 when only including tumours with baseline SUVmax > 5.0.
conclusionFDG PET is useful in guiding management of patients with suspected recurrence after SABR, particularly in cases where the tumour is FDG avid pre-treatment.
Indexed as
Identifiers
40498157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.